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Abstract: It is widely accepted that the endocrine hormone leptin controls food intake and energy
homeostasis via activation of leptin receptors expressed on hypothalamic arcuate neurons. The
hippocampal formation also displays raised levels of leptin receptor expression and accumulating
evidence indicates that leptin has a significant impact on hippocampal synaptic function. Thus,
cellular and behavioural studies support a cognitive enhancing role for leptin as excitatory synaptic
transmission, synaptic plasticity and glutamate receptor trafficking at hippocampal Schaffer collateral
(SC)-CA1 synapses are regulated by leptin, and treatment with leptin enhances performance in
hippocampus-dependent memory tasks. Recent studies indicate that hippocampal temporoammonic
(TA)-CA1 synapses are also a key target for leptin. The ability of leptin to regulate TA-CA1 synapses
has important functional consequences as TA-CA1 synapses are implicated in spatial and episodic
memory processes. Moreover, degeneration is initiated in the TA pathway at very early stages of
Alzheimer’s disease, and recent clinical evidence has revealed links between plasma leptin levels
and the incidence of Alzheimer’s disease (AD). Additionally, accumulating evidence indicates
that leptin has neuroprotective actions in various AD models, whereas dysfunctions in the leptin
system accelerate AD pathogenesis. Here, we review the data implicating the leptin system as a
potential novel target for AD, and the evidence that boosting the hippocampal actions of leptin may
be beneficial.
Keywords: Leptin; hippocampus; synaptic plasticity; tau; AMPA; Alzheimer’s; amyloid; memory;
synaptic transmission
1. Introduction
It is over 50 years since Hervey performed ground-breaking parabiosis experiments
which suggested that a circulatory factor regulates food intake and body weight [1]. This
factor has since been identified as the 16 kDa ob gene product, leptin, which is derived from
the Greek word leptos, meaning thin [2]. The major site for the production of leptin is white
adipose tissue, although leptin is also made in various other peripheral tissues, including
skeletal muscle, placenta and mammary epithelium. The circulating plasma levels of
leptin directly correlate to overall body fat content [3]. Although leptin is predominantly
produced by peripheral tissues, it readily gains entry to the brain via a saturable transport
process at the blood–brain barrier or via the cerebrospinal fluid [4]. Within the CNS,
specific hypothalamic nuclei such as the arcuate nucleus and ventromedial hypothalamus
are key targets for leptin. After a meal, circulating leptin levels increase, leading to a rise
in the CNS levels of leptin which in turn signals a feeling of fullness. In contrast, after
periods of starvation or fasting, the circulating leptin levels fall, which acts as a stimulus
for feeding [5].
Studies in this area have been aided by the availability of rodents with naturally
occurring mutations in the leptin and lepR genes. Mutations in the ob gene have been
shown to underlie early-onset obesity, hypothermia, and hyperphagia in mice. Thus,
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in ob/ob mice, there is a lack of leptin as a truncated leptin protein is generated that is
unable to be secreted. In a different leptin-deficient mouse strain (ob2J/ob2J), a transposon
is integrated into the ob gene, thereby preventing ob mRNA synthesis. Interestingly, ob gene
mutations rarely occur in humans. However, cases of morbid obesity identified in families
from Pakistan and Turkey have been linked to specific mutations in the ob gene. The low
incidence of leptin-specific mutations in humans indicates that genetic abnormalities in the
leptin system are not the principal route for the development of obesity in humans.
2. Leptin Receptors
2.1. Leptin Receptor Isoforms
Leptin produces its biological effects via activating the leptin receptor (LepR). Tartaglia
and colleagues first isolated LepR from the choroid plexus, and six isoforms of the receptor
have been identified (LepRa-f) [6]. The isoforms differ with respect to their C-terminal
domain length, which in turn influences the signalling capacity of the different LepR
isoforms. It is widely accepted that the long-form (LepRb) is the predominant signalling
competent isoform due to the extended length of its C-terminal domain. Conversely,
the short isoforms (LepRa,c,d,f) have shorter C-terminal domains and limited signalling
capacity. LepRe is distinct as it lacks a transmembrane domain but it is thought to be a
route for transporting leptin in the plasma, as it still retains leptin-binding capacity.
2.2. Leptin Receptor-Driven Signalling
LepRs are members of the class I cytokine receptor superfamily which signal via
association with janus tyrosine kinases (JAKs) [7]. Leptin binding to its receptor pro-
motes phosphorylation and subsequent activation of JAK2, leading to recruitment and
stimulation of various downstream pathways including phosphoinositide 3-kinase (PI3K),
ERK, and signal transducers and activators of transcription (STAT3). LepR signalling can
be terminated via activation of SOCS1-3 (suppressor of cytokine signalling), which bind
to phosphorylated JAK2, thereby limiting LepR-driven signalling [8]. In hippocampal
neurons, activation of PI3K, ERK and STAT3 are implicated in LepR-driven regulation of
synaptic function (Figure 1) [9].




Figure 1. Leptin receptor-driven signalling in neurons. The key signalling pathways activated following leptin binding to 
leptin receptors (LepRs) and subsequent activation of janus tyrosine kinase (JAK)2 are shown including signal transducers 
and activators of transcription (STAT3), Ras-Raf-MEK-MAPK and phosphoinositide 3-kinase (PI3K), which ultimately 
lead to gene transcriptional changes or altered ion channel function. LepR signalling is terminated following the produc-
tion of suppressor of cytokine signalling (SOCS)3. 
2.3. Leptin Receptor Expression in the CNS 
In accordance with leptin’s pivotal role in controlling energy homeostasis, LepRs are 
highly expressed in specific regions of the hypothalamus that govern food intake and 
body weight, such as arcuate nucleus and ventromedial hypothalamus [10,11]. Addition-
ally, high levels of LepR expression are observed in many other brain regions, including 
the hippocampus and cortex [12,13]. This pattern of LepR expression in the CNS suggests 
potential important roles for leptin in higher brain functions. Indeed, early studies involv-
ing leptin-deficient (ob/ob) mice demonstrated that absence of leptin resulted in neurode-
velopmental abnormalities, with specific impairments detected in hippocampal and cor-
tical brain regions [14]. These deficits were readily reversed by leptin replacement, sug-
gesting a role for leptin in neuronal development. In support of this hypothesis, a surge 
in leptin is observed during the critical period of postnatal development [15]. Subsequent 
studies in this area have identified that this postnatal leptin surge plays a critical role in 
development of key hypothalamic synaptic connections involved in control of energy ho-
meostasis [16]. However, increasing evidence indicates that the modulatory effects of lep-
tin are not restricted to early postnatal stages of development, as leptin is reported to 
markedly influence the functioning of the hippocampus in adulthood and during ageing. 
Thus, in adult, tissue treatment with leptin has a major impact on the cellular processes 
underlying hippocampal learning and memory, which has led to the proposal that this 
hormone acts as a potential cognitive enhancer [17,18]. In support of this possibility, def-
icits in hippocampus-specific processes, such as spatial learning and memory, accompany 
insensitivity to leptin [19,20].  
3. Leptin Regulation of Hippocampal Excitatory Synaptic Function 
3.1. SC-CA1 Synapses 
Immunocytochemical studies performed on cultured hippocampal neurons pro-
vided the first experimental evidence for expression of LepRs at hippocampal synapses 
[21], as LepR-positive immunolabelling was not only detected on principal CA1 neurons 
but also co-localised with the synaptic marker, synapsin-1. Subsequent electrophysiolog-
ical studies observed that application of leptin depressed excitatory synaptic transmission 
Figure 1. Leptin receptor-driven signal ing i . t a s activated fo lowing leptin binding to
leptin receptors (LepRs) and subsequent activatio f j t i i (J ) are sho n including signal transducers
and activators of transcription (STAT3), Ras-Raf-MEK-MAPK and phosphoinositide 3-kinase (PI3K), which ultimately lead
to gene transcriptional changes or altered ion channel function. LepR signalling is terminated following the production of
suppressor of cytokine signalling (SOCS)3.
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In rodents, LepR gene mutations result in leptin-insensitivity, which ultimately leads
to development of early-onset obesity as well as several endocrine-related impairments [2].
In db/db mice, a truncated form of LepR is produced which is unable to signal via the con-
ventional JAK-STAT signalling pathway. Conversely, in fa/fa rats, a single point mutation
occurs that renders all the LepR isoforms signalling incompetent [2]. In a manner similar to
the ob gene mutations, the incidence of human LepR gene mutations is also extremely low.
2.3. Leptin Receptor Expression in the CNS
In accordance with leptin’s pivotal role in controlling energy homeostasis, LepRs are
highly expressed in specific regions of the hypothalamus that govern food intake and body
weight, such as arcuate nucleus and ventromedial hypothalamus [10,11]. Additionally,
high levels of LepR expression are observed in many other brain regions, including the
hippocampus and cortex [12,13]. This pattern of LepR expression in the CNS suggests po-
tential important roles for leptin in higher brain functions. Indeed, early studies involving
leptin-deficient (ob/ob) mice demonstrated that absence of leptin resulted in neurodevel-
opmental abnormalities, with specific impairments detected in hippocampal and cortical
brain regions [14]. These deficits were readily reversed by leptin replacement, suggesting a
role for leptin in neuronal development. In support of this hypothesis, a surge in leptin is
observed during the critical period of postnatal development [15]. Subsequent studies in
this area have identified that this postnatal leptin surge plays a critical role in development
of key hypothalamic synaptic connections involved in control of energy homeostasis [16].
However, increasing evidence indicates that the modulatory effects of leptin are not re-
stricted to early postnatal stages of development, as leptin is reported to markedly influence
the functioning of the hippocampus in adulthood and during ageing. Thus, in adult, tissue
treatment with leptin has a major impact on the cellular processes underlying hippocampal
learning and memory, which has led to the proposal that this hormone acts as a potential
cognitive enhancer [17,18]. In support of this possibility, deficits in hippocampus-specific
processes, such as spatial learning and memory, accompany insensitivity to leptin [19,20].
3. Leptin Regulation of Hippocampal Excitatory Synaptic Function
3.1. SC-CA1 Synapses
Immunocytochemical studies performed on cultured hippocampal neurons provided
the first experimental evidence for expression of LepRs at hippocampal synapses [21],
as LepR-positive immunolabelling was not only detected on principal CA1 neurons but
also co-localised with the synaptic marker, synapsin-1. Subsequent electrophysiological
studies observed that application of leptin depressed excitatory synaptic transmission at
Schaffer-collateral (SC)-CA1 synapses in acute hippocampal slices obtained from juvenile
(P11-18) rats [22]; an effect that was readily reversed on washout of leptin. The ability
of leptin to reversibly depress hippocampal excitatory synaptic transmission at SC-CA1
synapses has been observed in mouse and rats at similar developmental stages [23,24]. In
P5-8 hippocampal slices, leptin induces a novel form of N-Methyl-D-aspartate (NMDA)
receptor-dependent long-term depression (LTD) [25]. In contrast, in adult hippocampus
(12–16 weeks), leptin has an opposing effect as it results in a long-lasting increase in
excitatory synaptic transmission that persists even after washout of leptin [25]. The ability
of leptin to induce long-term potentiation (LTP) at adult SC-CA1 synapses also requires
NMDA receptor activation as the effects of leptin are blocked by the competitive NMDA
receptor antagonist D-AP5 [24,25].
It has been hypothesised that activation of NMDA receptors comprised of different
subunits underlie different forms of activity-dependent synaptic plasticity. Indeed, the use
of specific pharmacological tools to block different NMDA receptor subunits revealed that
LTP requires stimulation of GluN2A subunits, whereas GluN2B subunits are implicated
in LTD [26,27]. Similarly, inhibition of GluN2B subunits with either ifenprodil or Ro25-
6081 blocked leptin-induced LTD at P5-8 hippocampal SC-CA1 synapses, suggesting
a crucial role for GluN2B subunits in this process. Activation of GluN2A subunits is
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also implicated in leptin-induced LTP at adult SC-CA1 synapses as treatment of slices
with the putative GluN2A antagonist, NVP-AAM077 completely blocked the ability of
leptin to induce LTP [24]. In addition to the involvement of distinct NMDA receptor
subunits, divergent signalling cascades are implicated in the bi-directional effects of leptin
on synaptic efficacy. Thus, activation of ERK signalling is pivotal for leptin-induced LTD,
whereas leptin-induced LTP in adult hippocampus requires stimulation of the PI3-kinase
pathway [24].
3.2. TA-CA1 Synapses
In addition to the SC input, hippocampal CA1 neurons are directly innervated by
the temporoammonic (TA) pathway, which extends from layer III of the entorhinal cortex
and forms synapses within the stratum-moleculare region of CA1. TA-CA1 synapses
are known to express high levels of dopamine receptors, and this feature can be used
in electrophysiological studies to readily identify TA-CA1 synaptic connections. Thus,
stimulation of TA-CA1 synapses can be verified by applying dopamine, which markedly
depresses excitatory synaptic transmission at TA-CA1 synapses but has no effect at SC-CA1
synapses [28,29]. Recent evidence indicates that in a manner similar to SC-CA1 synapses,
TA-CA1 synapses are also rapidly modulated by the hormone leptin. Thus, treatment of
juvenile hippocampal slices with leptin results in the induction of a novel form of LTP
at TA-CA1 synapses [29]. This contrasts with the synaptic depression induced by leptin
at SC-CA1 synapses at the same stage of development. However, both these forms of
leptin-driven synaptic plasticity require NMDA receptors and specifically activation of
GluN2B subunits [29] synapses as leptin-induced LTP at juvenile TA-CA1 synapses is
mediated by PI 3-kinase, not ERK, signalling.
In contrast to SC-CA1 synapses, at adult TA-CA1 synapses leptin has the ability to
induce a novel form of LTD, a process that is NMDA receptor-dependent and specifically
requires activation of GluN2A-containing NMDA receptors [30]. Moreover, activation of
canonical JAK2-STAT3 signalling and subsequent endocytosis of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors comprising GluA1 subunits is neces-
sary for leptin-induced LTD. This novel form of LTD shows parallels to activity-dependent
LTD induced at SC-CA1 synapses, as JAK-STAT signalling is also implicated in SC-CA1
LTD [31]. However, there are clear differences in the role of JAK-STAT3 in these two forms
of LTD as gene transcriptional changes underlie leptin-induced LTD at TA-CA1 synapses,
whereas NMDAR-dependent LTD induced at SC-CA1 synapses is independent of gene
transcriptional changes.
3.3. Leptin Regulation of AMPA Receptor Trafficking
It is widely recognised that synaptic insertion and removal of specific AMPA receptor
subunits play a key part in activity-dependent synaptic plasticity in the hippocampus [32].
Transient synaptic incorporation of GluA2-lacking AMPA receptors has also been reported
to accompany hippocampal LTP in some studies [33,34]. In accordance with the involve-
ment of AMPA receptor trafficking in activity-dependent LTP, the leptin-driven alteration
in synaptic efficacy at adult SC-CA1 synapses involves synaptic insertion of GluA2-lacking
AMPA receptors [25]. Thus, leptin-induced LTP is reversed by addition of specific inhibitors
of GluA2-lacking AMPA receptors, namely, philanthotoxin. In whole-cell recordings, leptin-
induced LTP is also associated with an increase in the rectification index of synaptic AMPA
receptors, suggesting incorporation of GluA2-lacking AMPA receptors mediates leptin-
induced LTP. In parallel studies performed in cultured hippocampal neurons and in acute
brain slices, exposure to leptin culminates in an increase in the plasma membrane expres-
sion as well as the synaptic expression of the AMPA receptor subunit, GluA1 [25]. Together,
these findings suggest that the ability of leptin to induce LTP at adult SC-CA1 synapses
involves trafficking of GluA2-lacking AMPA receptors into hippocampal synapses.
In a similar manner, trafficking and insertion of AMPA receptors into synapses play a
pivotal part in leptin-induced LTP at juvenile TA-CA1 synapses [26], as prior treatment with
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philanthotoxin blocked the ability of leptin to induce LTP. The leptin-driven persistent in-
crease in synaptic transmission was also reversed by addition of philanthotoxin, suggesting
that insertion of GluA2-lacking AMPA receptors is required for leptin-induced LTP. AMPA
receptor trafficking events also underlie the effects of leptin at adult TA-CA1 synapses, as
removal of GluA2-lacking AMPA receptors is key for induction of LTD by leptin [30]. To-
gether, these findings indicate that the ability of leptin to regulate the movement of AMPA
receptors to and away from hippocampal synapses is key for maintaining the bi-directional
effects of leptin on excitatory synaptic efficacy at TA- and SC-CA1 synapses (Figure 2).




Figure 2. Summary of the differential effects of leptin at Schaffer collateral (SC)-CA1 and temporo-
ammonic (TA)-CA1 synapses. Treatment of juvenile hippocampus with leptin results in a transient 
synaptic depression at SC-CA1 synapses that involves GluN2B activation and stimulation of ERK. 
Conversely, leptin induces LTP at juvenile TA-CA1 synapses, which requires GluN2A activation 
and PI 3-kinase-driven synaptic insertion of GluA2-lacking AMPA receptors. At adult SC-CA1 
synapses, leptin induces a novel form of LTP that is also NMDA receptor-dependent and involves 
synaptic insertion of GluA2-lacking AMPA receptors following inhibition of PTEN. In contrast, 
leptin induces long-term depression (LTD) at adult TA-CA1 synapses, and this process requires 
GluN2A activation and JAK2/STAT3 signalling, which results in AMPA receptor removal from 
synapses. 
4. Leptin and the Ageing Brain 
Numerous clinical studies have shown that during the human ageing process, there 
is a gradual decline in the functionality of metabolic systems. This has implications not 
only for the metabolic function of peripheral tissues, but as metabolic hormones have 
widespread actions in the CNS, deteriorations in metabolic function may impact not only 
overall brain health but also influence the risk of age-related neurodegeneration later in 
life. In this respect, there is good evidence supporting the notion that Alzheimer’s disease 
(AD) is related to dysfunctions in brain glucose metabolism which can lead to progressive 
and brain-region specific neuronal degeneration [35,36]. A growing body of evidence in-
dicates that alterations in leptin function are also correlated with AD. Indeed, clinical stud-
ies have identified lifestyle factors, like diet and body weight, as having a significant im-
pact on development of AD. In this respect, there is considerable evidence that weight 
gain or an obese phenotype in middle age increases AD risk [37–40]. In contrast, weight 
loss in elderly individuals is associated with a higher likelihood of AD [41–43], suggesting 
that body weight has a complex yet paradoxical effect on AD risk. It is interesting to note 
that the risk of developing other neurodegenerative conditions, like amyotrophic lateral 
sclerosis (ALS), is also influenced by body weight status [44,45].  
The link between body weight and neurodegeneration risk suggest a central role for 
adipose tissue, and adipokines like leptin, in determining clinical outcome across a spec-
trum of CNS disorders including AD. In support of leptin’s role in AD, the leptin system 
is altered in AD such that abnormally high as well as low leptin levels are reported in AD 
sufferers [46,47]. Moreover, in prospective studies, a lower incidence of AD was detected 
in individuals who had high circulating leptin levels in the absence of an obese phenotype 
[48]. Comparable correlations between leptin and neurodegeneration risk have been 
demonstrated in rodent models of AD, with APPSwe and CRND8 mouse models both 
displaying significantly lower circulating leptin levels than age-matched wild-type ani-
mals [49,50]. However, a complex picture is emerging of leptin’s role in AD as recent clin-
ical studies have failed to detect significant alterations in circulating leptin levels in AD 
Figure 2. Summary of the differential ffects of leptin at Schaffer collateral (SC)-CA1 and temporoammonic (TA)-CA1
synapses. Treatment of juvenile hippocampus with leptin res lts in a transient synapt c d ression a SC-CA1 synapses that
involves GluN2B ctivation and stimulation of ERK. Conversely, leptin induces LTP at juvenile TA-CA1 synapses, which
requires GluN2A activation and PI 3-kinase-driven synaptic insertion of GluA2-lacking AMPA receptors. At adult SC-CA1
synapses, leptin induces a novel form of LTP that is also NMDA receptor-dependent and involves synaptic insertion of
GluA2-lacking AMPA receptors following inhibition of PTEN. In contrast, leptin induces long-term depression (LTD) at
adult TA-CA1 synapses, and this process requires GluN2A activation and JAK2/STAT3 signalling, which results in AMPA
receptor removal from synapses.
The cellular mechanisms responsible for the insertion of GluA2-lacking AMPA re-
ceptors in response to leptin has been studied in detail. Thus, using a combination of
electrophysiology and immunocytochemical approaches, Moult and colleagues (2010) ob-
served that the leptin-driven increase in GluA1 surface expression was accompanied by
an elevation of the intracellular levels of the second messenger, phosphoinositide 3,4,5-
trisphosphate (PIP3). It is well known that PIP3 levels are regulated by the enzyme, PI
3-kinase which promotes conversion of phosphoinositide-4,5-bisphosphate (PIP2) into PIP3.
The phosphatase and tensin homolog (PTEN) also regulates intracellular PIP3 levels, as
PTEN activity counteracts the actions of PI 3-kinase, by dephosphorylating PIP3, which
in turn promotes the generation of PIP2. Inhibition of the phosphatase, PTEN, not only
mirrored the effects of leptin but it also occluded the ability of leptin to elevate PIP3 levels,
and to traffic GluA1 to hippocampal synapses, suggesting that leptin-driven inhibition of
PTEN underlies both events.
4. L ptin and the Ageing Brain
Numerous clinical studies have shown that during the human a eing process, there
is a gradu l decline in he functionality of metabolic systems. This has implications not
only for the metabolic f nction of peripheral ssues, but as metabolic hormones have
wide pread actio s in the CNS, deterior tions in metabolic function may impact not only
overall brain health but also i fl enc the risk f age-related neurodegenerati n later in life.
In this respect, th re s good evidence supporting the notion that Alzheimer’s disease (AD)
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is related to dysfunctions in brain glucose metabolism which can lead to progressive and
brain-region specific neuronal degeneration [35,36]. A growing body of evidence indicates
that alterations in leptin function are also correlated with AD. Indeed, clinical studies have
identified lifestyle factors, like diet and body weight, as having a significant impact on
development of AD. In this respect, there is considerable evidence that weight gain or an
obese phenotype in middle age increases AD risk [37–40]. In contrast, weight loss in elderly
individuals is associated with a higher likelihood of AD [41–43], suggesting that body
weight has a complex yet paradoxical effect on AD risk. It is interesting to note that the
risk of developing other neurodegenerative conditions, like amyotrophic lateral sclerosis
(ALS), is also influenced by body weight status [44,45].
The link between body weight and neurodegeneration risk suggest a central role
for adipose tissue, and adipokines like leptin, in determining clinical outcome across a
spectrum of CNS disorders including AD. In support of leptin’s role in AD, the leptin
system is altered in AD such that abnormally high as well as low leptin levels are reported
in AD sufferers [46,47]. Moreover, in prospective studies, a lower incidence of AD was
detected in individuals who had high circulating leptin levels in the absence of an obese
phenotype [48]. Comparable correlations between leptin and neurodegeneration risk have
been demonstrated in rodent models of AD, with APPSwe and CRND8 mouse models
both displaying significantly lower circulating leptin levels than age-matched wild-type
animals [49,50]. However, a complex picture is emerging of leptin’s role in AD as recent
clinical studies have failed to detect significant alterations in circulating leptin levels in AD
patients or a direct correlation between leptin and cognitive decline [39,51,52]. A range
of confounding factors, such as gender, diet, and exercise may have contributed to the
reported discrepancies in these studies. As metabolic function involves close interplay
between leptin and other endocrine hormones, like ghrelin and insulin, it is likely that the
relative levels of these hormones, as well underlying metabolic disorders, like diabetes, all
influence the overall risk of AD. Consequently, monitoring the plasma levels of leptin in
isolation, may not be the best determinant of AD risk.
In addition to age-related changes in metabolic function, alterations in neuronal re-
sponsiveness to metabolic hormones with age have been observed. Indeed, numerous
studies have identified significant reductions in the insulin system, including downregula-
tion of receptors and associated signalling cascades, as a result of the ageing process [53,54].
In accordance with this, deterioration in leptin responsiveness and leptin receptor func-
tionality are also associated with the ageing process. For instance, studies in hypothalamic
neurons demonstrated that the ability of leptin to regulate satiety is markedly reduced in
aged compared to adult rats [55] and altered hypothalamic leptin-responsiveness is linked
to diminished capacity to stimulate STAT3 signalling [56]. Significant changes in leptin
function are also observed in the hippocampus with age. Thus, studies comparing the
age-related effects of leptin on hippocampal synaptic function detected marked variance in
hippocampal responsiveness to leptin between 3–4 month and 12–14 month of age, such
that the magnitude of LTP evoked by leptin at 12–14 month was ~50% less than leptin-
induced LTP at 3–4 month of age [24]. As NMDA receptor activation is a pre-requisite
for leptin-induced LTP, and it is known that NMDA receptor function declines with age,
it is feasible that a decrease in the ability of leptin to enhance NMDA receptor function
contributes to the attenuated leptin-responsiveness with age, although this remains to be
determined experimentally.
4.1. Neuroprotective Actions of Leptin
Comparative studies performed in leptin-sensitive and leptin-deficient rodents were
some of the first to uncover possible neuroprotective actions of leptin. Significant CNS
changes including a fall in brain weight were detected in ob/ob mice relative to wildtype
littermates, suggesting decreased neuronal viability is associated with a lack of leptin [14].
This role of leptin was further verified by the complete reversal of these brain abnormalities
after treatment with leptin. Numerous studies have since confirmed a neuroprotective role
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for leptin, with leptin-based treatments linked to enhanced survival of neurons as well as
reduced neuronal apoptosis in response to various toxic agents [57–59]. Recent evidence
indicates that leptin-driven improvements in mitochondrial function may contribute to
leptin-driven increases in neuronal viability [60]. Accumulating evidence indicates that
leptin displays neurotrophic properties, but this may be restricted to specific neuronal
populations and brain regions. For example, leptin is reported to selectively promote
neurite outgrowth from cerebellar purkinje, but not granule, cells [61].
The neuroprotective effects of leptin extend to various models of CNS-driven disease
including models of ischaemia [62–64]. Indeed, after transient periods of ischaemia, treat-
ment with leptin is reported to reduce the size of cerebral infarcts and degree of brain
oedema [65]. Leptin treatment also promotes an increase in the levels of ATP and p-Akt, at
the same time as reducing the levels of lactate dehydrogenase, which will ultimately lead
to overall enhanced neuronal cell survival in ischaemic stroke models.
Protective actions of leptin have been observed in several neurodegenerative models
that replicate key pathological features of Parkinson’s disease [57,66,67] and AD [50,68,69].
In AD, build-up of toxic β-amyloid (Aβ) is known to promote formation of amyloid
plaques, and that accumulation of Aβ involves proteolytic processing of amyloid precursor
protein (APP), with specific generation of the toxic forms of Aβ driven by sequential β-
and γ-secretase cleavage of APP. Expression of β- and γ-secretase is downregulated by
leptin, which would lead to reduced levels of toxic Aβ, due to enhanced APP cleavage
by α-secretase [70–72]. Studies in neuronal cells have demonstrated that leptin directly
interferes with Aβ levels via blocking β-secretase action [72]. Leptin also diminishes the
extracellular levels of Aβ by driving Aβ uptake into cells [73] (Figure 3). Furthermore,
treatment of an AD rodent model with leptin gives rise to a significant reduction in brain
amyloid load [68]. Introduction of leptin into APP/PS1 mice using lentiviral gene therapy
approaches results in an overall decrease in Aβ accumulation as well as recovery of some of
the AD-related synaptic deficits [74,75]. Together, these studies indicate that leptin not only
interferes with APP-dependent generation of Aβ but it also limits its toxic accumulation
in neurons.
Pharmaceuticals 2021, 14, x FOR PEER REVIEW 8 of 15 
 
 
directly interferes with Aβ levels via blocking β-secretase action [72]. Leptin also dimin-
ishes the extracellular levels of Aβ by driving Aβ uptake into cells [73] (Figure 3). Further-
more, treatme t of an AD rodent model with leptin giv s rise to a significant reduction in 
brain amyloid load [68]. Intr duction of leptin into APP/PS1 mice using lentiviral gene 
therapy approaches results in an ov rall decrease in Aβ accumulation as well as rec very 
of some of the AD-related synaptic deficits [74,75]. Together, these studies indicate that 
leptin not only interferes with APP-dependent generation of Aβ but it also limits its toxic 
accumulation in neurons. 
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(APP) by the sequential actions of Beta secretase-1 (BACE1) and γ-secretase generates Aβ protein that readily aggregates 
into oligomeric forms of Aβ. Acute exposure to Aβ oligomers promotes toxic actions at synapses that include tau phos-
phorylation, AMPA receptor endocytosis, and block of hippocampal LTP. Chronic exposure to Aβ leads to plaque for-
mation and enhanced cell death. Leptin prevents the acute effects of Aβ on synaptic function, and it limits Aβ production 
and overall brain load, by reducing BACE1 activity, and promoting degradation of Aβ. 
Another key pathological feature of AD is the formation of neurofibrillary tangles, 
composed of hyper-phosphorylated tau. One of the key enzymes that regulate the phos-
phorylation status of tau is glycogen synthase kinase 3β (GSK3β), a serine/threonine pro-
tein kinase, which is inhibited by PI 3-kinase. Recent studies indicate that leptin inhibits 
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of p-tau are observed in cortical tissue from Zucker fa/fa rats compared to Zucker lean rats, 
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display resistance to leptin also exhibit elevated levels of p-tau compared to wild-type 
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enhances phosphorylation of tau.  
4.2. Leptin Prevents Aβ-Driven Impairments at Hippocampal Synapses 
It is well established that acute exposure to oligomeric Aβ1-42 has damaging effects at 
excitatory synapses. Indeed, one consequence of treating brain slices with Aβ1-42 is that 
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dependent induction of LTD is facilitated in slices exposed to Aβ1-42 and this process is 
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Figure 3. tin prevents the aberrant toxic effects of β-amyloid (Aβ) at ynapses. Cleavage f amyloid precursor
protein (APP) by the sequential actions of Beta secretase-1 (BACE1) and γ-secretase generates Aβ protein that re dily
aggregates into oligomeric forms of Aβ. Acute exposure to Aβ oligomers promotes toxic actions at synapses that include
tau phosphorylation, AMPA receptor endocytosis, and block of hippocampal LTP. Chronic exposure to Aβ leads to plaque
formation and enhanced cell death. Leptin prevents the acute effects of Aβ on synaptic function, and it limits Aβ production
and overall brain load, by reducing BACE1 activity, and promoting degradation of Aβ.
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Another key pathological feature of AD is the formation of neurofibrillary tangles,
composed of hyper-phosphorylated tau. One of the key enzymes that regulate the phospho-
rylation status of tau is glycogen synthase kinase 3β (GSK3β), a serine/threonine protein
kinase, which is inhibited by PI 3-kinase. Recent studies indicate that leptin inhibits activa-
tion of GSK3β, via stimulation of PI 3-kinase, and that activation of this LepR-signalling
pathway limits tau phosphorylation [73,76]. Exposure to leptin is also reported to decrease
the levels of phosphorylated tau (p-tau) in rodent models of AD [73]. The ability of leptin to
regulate the levels of p-tau is supported by histological studies as raised levels of p-tau are
observed in cortical tissue from Zucker fa/fa rats compared to Zucker lean rats, suggesting
that leptin-insensitivity boosts tau phosphorylation [77]. Transgenic mice that display
resistance to leptin also exhibit elevated levels of p-tau compared to wild-type controls [78].
These findings provide further verification that lack or insensitivity to leptin enhances
phosphorylation of tau.
4.2. Leptin Prevents Aβ-Driven Impairments at Hippocampal Synapses
It is well established that acute exposure to oligomeric Aβ1-42 has damaging effects at
excitatory synapses. Indeed, one consequence of treating brain slices with Aβ1-42 is that
there is inhibition of LTP at hippocampal SC-CA1 synapses [79]. Additionally, activity-
dependent induction of LTD is facilitated in slices exposed to Aβ1-42 and this process is
thought to involve the Aβ1-42-driven removal of synaptic AMPA receptors [80]. Recent
electrophysiological studies indicate that prior treatment of acute hippocampal slices with
leptin prevents these aberrant effects of Aβ such that the ability of Aβ1-42 to inhibit LTP
and to facilitate LTD is blocked by leptin [77]. Moreover, exposure of cultured hippocampal
neurons to leptin prevents Aβ1-42-driven removal of GluA1-containing AMPA receptors
from hippocampal synapses [77]. PI 3-kinase is implicated in the protective actions of
leptin at synapses as the beneficial effect of leptin in preventing Aβ1-42 inhibition of LTP
is blocked by pharmacological inhibition of PI 3-kinase. The capacity of leptin to limit
Aβ1-42-driven AMPA receptor endocytosis is also hindered by PI 3-kinase inhibitors [77].
As exposure to Aβ1-42 promotes cleavage of Akt, which in turn limits inhibition of GSK-
3β [81], it is feasible that leptin counteracts this chain of events via activation of PI 3-kinase
and subsequent inhibition of GSK-3β. In support of this possibility, administration of
pharmacological inhibitors of GSK-3β not only replicate but also occlude the effects of
leptin [73].
4.3. Leptin Improves Hippocampus-Dependent Learning and Memory
It is widely accepted that activity-dependent synaptic plasticity is likely to be a key
cellular process involved in hippocampal-dependent learning and memory [82]. As signifi-
cant evidence now suggests that leptin facilitates the same cellular events that underpin
hippocampal learning and memory, it is likely that leptin also influences hippocampus-
dependent behaviours. Indeed, several studies have observed improved performance in
various hippocampus-dependent learning and memory tasks in rodents treated with leptin.
Thus, the ability of rodents to perform spatial memory tasks in the Morris water maze
improves after intravenous administration of leptin [83], whereas insensitivity to leptin
is associated with impaired performance in hippocampus-specific memory tasks [19,20].
Dietary changes that lead to leptin resistance in rodents are also associated with significant
impairments in novel object recognition tasks [84]. Conversely, peripheral administration
of leptin enhances the ability of mice to recognize novel objects [85].
Numerous studies support the notion that the detrimental effects of Aβ1-42 on hip-
pocampal synaptic function result in cognitive impairments, and these events closely
correlate with the memory deficits and impaired cognitive function that occur in human
cases of AD. In accordance with leptin’s ability to prevent the aberrant actions of Aβ1-42 at
hippocampal synapses, treatment with leptin also improves cognitive function in rodent
models of AD. Thus, direct administration of leptin into the hippocampal formation boosts
memory retention in SAMP8 mice, as evidenced by improved performance in T-maze and
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passive avoidance behavioural paradigms [49]. Performance in novel object recognition
assays is also improved in CRND8 transgenic mice in response to leptin treatment [73].
Furthermore, deficits in spatial memory due to intracerebroventricular application of toxic
Aβ1-42 are attenuated in rats following treatment with leptin [69]. In addition, lentiviral
administration of leptin directly into brain ventricles counteracts the reported impairments
in hippocampal-dependent memory in APP/PS1 transgenic mice [75]. Consequently, there
is now good evidence from studies in wild-type animals and in various disease models
that leptin augments cognitive function and specifically enhances hippocampus-driven
memory processes.
5. Targeting the Leptin System as a Novel Therapeutic in AD?
Leptin is known to be safe for human use and it is already licensed as an anti-obesity
treatment. Clinical studies where leptin has been used to treat obesity have identified that
leptin also exhibits beneficial cognitive properties, which parallel the cognitive-enhancing
actions of leptin in rodents. Thus, in functional brain imaging studies of individuals with
congenital leptin deficiencies, Matochik and colleagues [86] found that leptin treatment en-
hanced gray matter volume, which is indicative of improved cognitive function. Moreover,
cognitive deficits in a 5-year-old child, who was unable to produce leptin due to a leptin
(ob) gene mutation, also markedly improved in response to a leptin treatment strategy [87].
These studies reiterate that leptin-based therapies are safe for use in humans, but also that
leptin can readily penetrate the CNS and target key brain regions, like the hippocampus,
that are key for higher cognitive functions. Although there is now good experimental
evidence supporting the beneficial effects of leptin in AD models, studies in human AD
patients have yet to be performed and thus the potential therapeutic efficacy of leptin in
AD remains to be examined in a clinical setting. However, given what is already known
about the central actions of leptin, it is feasible that not all AD patients would respond to
leptin-based therapies. Consequently, identifying patients who would likely benefit would
be crucial in clinical trials. Thus, individuals with midlife obesity and leptin resistance may
not respond, whereas treatment with leptin may offer significant benefit to patients with
low circulating leptin levels.
One area that offers new hope for an AD therapy is in the possible use of leptin-
based peptide molecules that mimic the actions of leptin. In this respect, fragments of
the whole leptin molecule have already been identified as having anti-obesity actions in
various studies [88,89]. Recent studies have extended these findings to show that one
specific leptin fragment, namely, leptin116-130, not only displays hippocampal bioactivity
but it replicates the cognitive-enhancing actions of leptin by facilitating the induction of
hippocampal LTP, and by driving insertion of GluA1-containing AMPA receptors into
synapses [85]. In addition, mice perform much better in episodic-like memory tasks after
peripheral administration of leptin116-130, compared to mice treated with vehicle. Moreover,
leptin’s neuroprotective actions are mirrored by leptin116-130, as treatment with this leptin
fragment prevents the detrimental effects of Aβ1-42 as the ability of Aβ1-42 to prevent
hippocampal LTP induction and to promote internalization of GluA1 subunits are blocked
by leptin116-130 [85]. Although these findings are promising, further pre-clinical studies in
rodent models of AD are required, before verifying that leptin116-130, or related peptides
are suitable clinical targets.
6. Protective Actions of Leptin in Other Neurodegenerative Diseases
In accordance with the proposed link between metabolic imbalance, mid-life obesity
and risk of AD, several other neurodegenerative conditions are also associated with al-
tered metabolic status, including PD, Huntington’s disease (HD) and multiple sclerosis
(MS) [90–93]. Furthermore, the plasma levels of leptin are significantly reduced in HD and
PD patients [94–96], suggesting that functioning of the leptin system is modified in these
CNS disorders. Parallel changes in leptin function are also observed in rodent models of PD,
with attenuated leptin levels and metabolic dysfunction key reported features of mutant
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α-synuclein mice [97]. In relapsing MS patients, elevated levels of LepR expression as well
as LepR signalling via STAT3 have been detected in T cells and monocytes, suggesting a
possible role for leptin in MS relapse [98].
Recent studies also suggest a link between leptin and degenerative conditions affecting
motor neurons, as leptin levels are elevated in ALS patients [99] and in children with spinal
muscular atrophy [100]. In addition, population-based studies of German ALS patients
have revealed a relationship between leptin levels and the risk of developing ALS [101].
Moreover, recent studies indicate that reducing leptin levels improves lifespan and reduces
motor neuron degeneration in mutant superoxide dismutase 1 (SOD1) mice, suggesting
that altering leptin levels mitigates motor neuron disease progression [102].
7. Conclusions
The neuronal actions of the metabolic hormone leptin are known to extend beyond the
hypothalamus and energy homeostasis, to the hippocampal formation where leptin boosts
cognitive function. In addition to regulating classical SC-CA1 synapses that play a role in
spatial memory, TA-CA1 synapses have been identified as an important target for leptin.
As the TA input to CA1 neurons is implicated in episodic memory, the ability of leptin to
regulate this synaptic connection is likely to also influence episodic memory processes. It is
widely recognized that body weight, and dysfunctions in metabolic systems, have a role to
play in development of AD, and evidence from clinical studies has uncovered correlations
between the plasma levels of leptin and the risk of AD. In addition, accumulating evidence
indicates beneficial cognitive and neuroprotective effects of leptin and leptin fragments
in a variety of different rodent models of AD. Consequently, targeting the leptin system
may offer a novel therapeutic avenue for the development of an effective AD treatment.
However, in the absence of clinical assessment, it is unclear how effective leptin would
be. It is likely that a leptin-based therapy would not benefit individuals displaying leptin
resistance, nevertheless, there are potential therapeutic benefits of leptin in AD patients
with low leptin levels. Furthermore, these benefits are not restricted to AD as emerging
studies suggest that other neurodegenerative diseases, like ALS, are also associated with
metabolic imbalance and abnormalities in the leptin system. Further studies are needed
to examine thoroughly the therapeutic potential of the leptin system in AD and other
neurodegenerative disorders.
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